What do we know about the variability in survival of patients with amyotrophic lateral sclerosis?

References

• Brown RH, Al-Chalabi A, Longo DL. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162–172.
   PubMed Web of Science ®Google Scholar
• Blokhuis AM, Groen EJ, Koppers M, et al. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(6):777–794.
   PubMed Web of Science ®Google Scholar
• Braak H, Brettschneider J, Ludolph AC, et al. Amyotrophic lateral sclerosis–a model of corticofugal axonal spread. Nat Rev Neurol. 2013;9(12): 708–714.
   PubMed Web of Science ®Google Scholar
• Devine MS, Kiernan MC, Heggie S, et al. Study of motor asymmetry in ALS indicates an effect of limb dominance on onset and spread of weakness, and an important role for upper motor neurons. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7–8):481–487.
   PubMed Web of Science ®Google Scholar
• Devine MS, Ballard E, O’Rourke P, et al. Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3–4):84–90.
   Web of Science ®Google Scholar
• Spataro R, Re M L, Piccoli T, et al. Causes and place of death in Italian patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2010;122(3):217–223.
   PubMed Web of Science ®Google Scholar
• Gil J, Funalot B, Verschueren a, et al. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. Eur J Neurol. 2008;15(11):1245–1251.
   PubMed Web of Science ®Google Scholar
• Burkhardt C, Neuwirth C, Sommacal A, et al. Is survival improved by the use of NIV and peg in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. PloS One. 2017;12(5):e0177555.
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65(Suppl 1):S3–S9.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Jones A, Troakes C, et al. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012;124(3):339–352.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang X, Song L, et al. Autophagy dysregulation in amyotrophic lateral sclerosis. Brain Pathol. 2012;22(1):110–116.
   PubMed Web of Science ®Google Scholar
• Droppelmann CA, Campos-Melo D, Ishtiaq M, et al. RNA metabolism in ALS: when normal processes become pathological. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5–6):321–336.
   PubMed Web of Science ®Google Scholar
• Serio A, Concise Review: PR. The Cellular conspiracy of amyotrophic lateral sclerosis. Stem Cells. 2018;36(3):293–303.
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Komine O. The Multi-dimensional roles of astrocytes in ALS. Neurosci Res. 2018;126:31–38.
   PubMed Web of Science ®Google Scholar
• Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol. 1999;58(5):459–471.
   PubMed Web of Science ®Google Scholar
• Guegan C, Przedborski S. Programmed cell death in amyotrophic lateral sclerosis. J Clin Invest. 2003;111(2):153–161.
   PubMed Web of Science ®Google Scholar
• Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol. 2001;27(4):257–274.
   PubMed Web of Science ®Google Scholar
• Ilzecka J. Serum Caspase-9 Levels Are Increased in Patients with Amyotrophic Lateral Sclerosis. Neurol Sci. 2012;33:825-828.
   PubMedGoogle Scholar
• Fayaz SM, Suvanish Kumar VS, Rajanikant GK. Necroptosis: who knew there were so many interesting ways to die? CNS Neurol Disord Drug Targets. 2014;13(1):42–51.
   PubMed Web of Science ®Google Scholar
• Conrad M, Pratt DA. The Chemical basis of ferroptosis. Nat Chem Biol. 2019;15(12):1137–1147.
   PubMed Web of Science ®Google Scholar
• Devos D, Moreau C, Kyheng M, et al. A Ferroptosis-based panel of prognostic biomarkers for amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):2918.
   PubMedGoogle Scholar
• Geloso MC, Corvino V, Marchese E, et al. The dual role of microglia in als: mechanisms and therapeutic approaches. Front Aging Neurosci. 2017;9:242.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Wray NR, Henderson RD. Extra-motor abnormalities in amyotrophic lateral sclerosis: another layer of heterogeneity. Expert Rev Neurother. 2011;17:561-5677.
   Google Scholar
• Xu Z, Alruwaili ARS, Henderson RD, et al. Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival. J Neurol Sci. 2017;376:16–23.
   PubMed Web of Science ®Google Scholar
• Alruwaili AR, Pannek K, Coulthard a, et al. A combined tract-based spatial statistics and voxel-based morphometry study of the first MRI scan after diagnosis of amyotrophic lateral sclerosis with subgroup analysis. J Neuroradiol. 2018;45(1):41–48.
   PubMed Web of Science ®Google Scholar
• Loeffler JP, Picchiarelli G, Dupuis L, et al. The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol. 2016;26(2):227–236.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in als. Curr Mol Med. 2011;11(3):246–254.
   PubMed Web of Science ®Google Scholar
• Ioannides ZA, Ngo ST, Henderson RD, et al. Altered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progression. Neurodegener Dis. 2016;16(5–6):382–397.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Henderson RD, Lee A, et al. Gut microbiota in als: possible role in pathogenesis? Expert Rev Neurother. 2019;19:785-805.
   PubMed Web of Science ®Google Scholar
• Marangi G, Traynor BJ. Genetic causes of amyotrophic lateral sclerosis: new genetic analysis methodologies entailing new opportunities and challenges. Brain Res. 2015;14:75–93.
   Google Scholar
• Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17–23.
   PubMed Web of Science ®Google Scholar
• Ingre C, Roos PM, Piehl F, et al. Risk Factors for Amyotrophic Lateral Sclerosis. Clin Epidemiol. 2015;7:181–193.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi a, Calvo a, Chio a, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13(11): 1108–1113.
   PubMed Web of Science ®Google Scholar
• Chio A, Mazzini L, D’Alfonso S, et al. The multistep hypothesis of als revisited: the role of genetic mutations. Neurology. 2018;91(7):e635–e42.
   PubMed Web of Science ®Google Scholar
• Taylor JP, Brown RH Jr., Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197–206.
   PubMed Web of Science ®Google Scholar
• Nguyen HP, Van Broeckhoven C, van der Zee J. Als genes in the genomic era and their implications for FTD. Trends Genet. 2018;34(6):404–423.
   PubMed Web of Science ®Google Scholar
• Kuuluvainen L, Kaivola K, Monkare S, et al. Oligogenic basis of sporadic ALS: the example of SOD1 p.ala90val mutation. Neurology. Genetics. 2019;5:e335.
   Web of Science ®Google Scholar
• van Blitterswijk M, van Es MA, Hennekam EAM, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet. 2010;17(17):984–989.
   Google Scholar
• Giannoccaro MP, Bartoletti-Stella A, Piras S, et al. Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to c9orf72 repeat expansion: further observations on their oligogenic nature. J Neurol. 2017;264(7):1426–1433.
   PubMed Web of Science ®Google Scholar
• Morgan S, Shatunov A, Sproviero W, et al. A Comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the Uk. Brain. 2017;140(6):1611–1618.
   PubMedGoogle Scholar
• Garton FC, Benyamin B, Zhao Q, et al. Whole exome sequencing and DNA methylation analysis in a clinical amyotrophic lateral sclerosis cohort. Mol Genet Genomic Med. 2017;5(4):418–428.
   PubMed Web of Science ®Google Scholar
• van Rheenen W, Shatunov a, Dekker AM, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48(9):1043–1048.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Fang F, Hanby MF, et al. An Estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry. 2010;81(12):1324–1326.
   PubMed Web of Science ®Google Scholar
• Ryan M, Heverin M, McLaughlin RL, et al. Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2019;76(11):1367.
   PubMed Web of Science ®Google Scholar
• Wingo TS, Cutler DJ, Yarab N, et al. The heritability of amyotrophic lateral sclerosis in a clinically ascertained united states research registry. PloS One. 2011;6:e27985.
   PubMed Web of Science ®Google Scholar
• Trabjerg BB, Garton FC, van Rheenen W, et al. ALS in Danish registries: heritability and links to psychiatric and cardiovascular disorders. Neurol Genet. 2020;6(2):e398.
   PubMed Web of Science ®Google Scholar
• Byrne S, Heverin M, Elamin M, et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann Neurol. 2013;74(5):699–708.
   PubMed Web of Science ®Google Scholar
• O’Brien M, Burke T, Heverin M, et al. Clustering of neuropsychiatric disease in first-degree and second-degree relatives of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2017;74(12):1425–1430.
   PubMed Web of Science ®Google Scholar
• Chen X, Yazdani S, Piehl F, et al. Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging. 2018;67:202.e1-.e6.
   Web of Science ®Google Scholar
• Bandres-Ciga S, Noyce AJ, Hemani G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85(4):470–481.
   PubMed Web of Science ®Google Scholar
• Belbasis L, Bellou V, Evangelou E. Environmental risk factors and amyotrophic lateral sclerosis: an umbrella review and critical assessment of current evidence from systematic reviews and meta-analyses of observational studies. Neuroepidemiology. 2016;46(2):96–105.
   PubMed Web of Science ®Google Scholar
• Korner S, Kammeyer J, Zapf A, et al. Influence of environment and lifestyle on incidence and progress of amyotrophic lateral sclerosis in a German als population. Aging Dis. 2019;10(205–16):205.
   PubMedGoogle Scholar
• Weisskopf MG, McCullough ML, Calle EE, et al. Prospective Study of Cigarette Smoking and Amyotrophic Lateral Sclerosis. Am J Epidemiol. 2004;160(1):26–33.
   PubMed Web of Science ®Google Scholar
• Fang F, Quinlan P, Ye W, et al. Workplace Exposures and the Risk of Amyotrophic Lateral Sclerosis. Environ Health Perspect. 2009;117(9):1387–1392.
   PubMed Web of Science ®Google Scholar
• Wang MD, Gomes J, Cashman NR, et al. A meta-analysis of observational studies of the association between chronic occupational exposure to lead and amyotrophic lateral sclerosis. J Occup Environ Med. 2014;56(12):1235–1242.
   PubMed Web of Science ®Google Scholar
• Visser AE, D’Ovidio F, Peters S, et al. Multicentre, population-based, case-control study of particulates, combustion products and amyotrophic lateral sclerosis risk. J Neurol Neurosurg Psychiatry. 2019;90(8):854–860.
   PubMed Web of Science ®Google Scholar
• Morahan JM, Pamphlett R. Amyotrophic lateral sclerosis and exposure to environmental toxins: an Australian case-control study. Neuroepidemiology. 2006;27(3):130–135.
   PubMed Web of Science ®Google Scholar
• Roberts AL, Johnson NJ, Cudkowicz ME, et al. Job-related formaldehyde exposure and als mortality in the USA. J Neurol Neurosurg Psychiatry. 2016;87(7):786–788.
   PubMed Web of Science ®Google Scholar
• Seelen M, van Doormaal PT, Visser AE, et al. Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol. 2014;261(10):1949–1956.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen L, Fan D. The protective role of pre-morbid type 2 diabetes in patients with amyotrophic lateral sclerosis: a center-based survey in china. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:209-15.
   PubMed Web of Science ®Google Scholar
• Zeng P, Wang T, Zheng J, et al. Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from mendelian randomization using GWAS summary statistics. BMC Med. 2019;17(1):225.
   PubMed Web of Science ®Google Scholar
• Visser AE, Seelen M, Hulsbergen a, et al. Exploring the fitness hypothesis in als: a population-based case-control study of parental cause of death and lifespan. J Neurol Neurosurg Psychiatry. 2017;88(7):550–556.
   PubMed Web of Science ®Google Scholar
• Turner MR, Parton MJ, Shaw CE, et al. Prolonged survival in motor neuron disease: a descriptive study of the king’s database 1990-2002. J Neurol Neurosurg Psychiatry. 2003;74(7):995–997.
   PubMed Web of Science ®Google Scholar
• Pupillo E, Messina P, Logroscino G, et al. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol. 2014;75(2):287–297.
   PubMed Web of Science ®Google Scholar
• Beghi E, Mennini T, Bendotti C, et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem. 2007;14(30):3185–3200.
   PubMed Web of Science ®Google Scholar
• Thijs V, Peeters E, Theys P, et al. Demographic characteristics and prognosis in a flemish amyotrophic lateral sclerosis population. Acta Neurol Belg. 2000;100(2):84–90.
   PubMed Web of Science ®Google Scholar
• Dietrich-Neto F, Callegaro D, Dias-Tosta E, et al. Amyotrophic lateral sclerosis in Brazil: 1998 national survey. Arq Neuropsiquiatr. 2000;58(3A):607–615.
   PubMed Web of Science ®Google Scholar
• Loureiro MP, Gress CH, Thuler LC, et al. Clinical aspects of amyotrophic lateral sclerosis in Rio de Janiero/Brazil. J Neurol Sci. 2012;316(1–2):61–66.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang B, Chen R, et al. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in china. J Neurol Neurosurg Psychiatry. 2015;86(10):1075–1081.
   PubMed Web of Science ®Google Scholar
• Zhou S, Zhou Y, Qian S, et al. Amyotrophic lateral sclerosis in beijing: epidemiologic features and prognosis from 2010 to 2015. Brain Behav. 2018;8(11):e01131.
   PubMed Web of Science ®Google Scholar
• Zapata-Zapata CH, Franco Dager E, Aguirre-Acevedo DC, et al. Prevalence, incidence, and clinical-epidemiological characterization of amyotrophic lateral sclerosis in antioquia: colombia. Neuroepidemiology. 2019;1–7.
   Web of Science ®Google Scholar
• Christensen PB, Hojer-Pedersen E, Jensen NB. Survival of Patients with Amyotrophic Lateral Sclerosis in 2 Danish Counties. Neurology. 1990;40(4):600–604.
   PubMed Web of Science ®Google Scholar
• Chhetri SK, Bradley BF, Majeed T, et al. Motor Neurone Disease in Lancashire and South Cumbria in North West England and an 8 Year Experience with Enteral Nutrition. J Clin Neurosci. 2016;24:47–51.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Salachas F, Bruneteau G, et al. Improving Survival in a Large French Als Center Cohort. J Neurol. 2012;259(9):1788–1792.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Polychronopoulos P, Papapetropoulos S, et al. Clinical and Epidemiological Features of Motor Neuron Disease in South-Western Greece. Acta Neurol Scand. 2005;111(2):108–113.
   PubMed Web of Science ®Google Scholar
• Fong KY, Yu YL, Chan YW, et al. Motor Neuron Disease in Hong Kong Chinese: epidemiology and Clinical Picture. Neuroepidemiology. 1996;15(5):239–245.
   PubMed Web of Science ®Google Scholar
• Nalini a, Thennarasu K, Gourie-Devi M, et al. Clinical Characteristics and Survival Pattern of 1,153 Patients with Amyotrophic Lateral Sclerosis: experience over 30 Years from India. J Neurol Sci. 2008;272(1–2):60–70.
   PubMed Web of Science ®Google Scholar
• Sajjadi M, Etemadifar M, Nemati A, et al. Epidemiology of Amyotrophic Lateral Sclerosis in Isfahan, Iran. Eur J Neurol. 2010;17(7):984–989.
   PubMed Web of Science ®Google Scholar
• Gubbay SS, Kahana E, Zilber N, et al. Amyotrophic Lateral Sclerosis a Study of Its Presentation and Prognosis.. J Neurol. 1985;232(5):295–300.
   PubMed Web of Science ®Google Scholar
• Bandettini Di Poggio M, Sormani MP, Truffelli R, et al. Clinical Epidemiology of ALS in Liguria, Italy. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(1):52–57.
   PubMed Web of Science ®Google Scholar
• Kanai K, Shibuya K, Sato Y, et al. Motor Axonal Excitability Properties Are Strong Predictors for Survival in Amyotrophic Lateral Sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(7):734–738.
   PubMed Web of Science ®Google Scholar
• Jun KY, Park J, Oh KW, et al. Epidemiology of ALS in Korea Using Nationwide Big Data. J Neurol Neurosurg Psychiatry. 2019;90(4):395–403.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan K, Ashok PP, Sridharan R, et al. Descriptive Epidemiology of Motor Neuron Disease in Benghazi, Libya. Neuroepidemiology. 1986;5(1):47–54.
   PubMedGoogle Scholar
• Sanchez-Martinez CM, Choreno-Parra JA, Nunez-Orozco L, et al. A Retrospective Study of the Clinical Phenotype and Predictors of Survival in Non-Caucasian Hispanic Patients with Amyotrophic Lateral Sclerosis. BMC Neurol. 2019;19(1):261.
   PubMed Web of Science ®Google Scholar
• Murphy M, Quinn S, Young J, et al. Increasing Incidence of ALS in Canterbury, New Zealand: a 22-Year Study. Neurology. 2008;71(23):1889–1895.
   PubMed Web of Science ®Google Scholar
• Osuntokun BO, Adeuja AO, Bademosi O. The Prognosis of Motor Neuron Disease in Nigerian Africans a Prospective Study of 92 Patients. Brain. 1974;97(1):385–394.
   PubMedGoogle Scholar
• Tysnes OB, Vollset SE, Aarli JA. Epidemiology of Amyotrophic Lateral Sclerosis in Hordaland County, Western Norway. Acta Neurol Scand. 1991;83(5):280–285.
   PubMed Web of Science ®Google Scholar
• Benjaminsen E, Alstadhaug KB, Gulsvik M, et al. Amyotrophic Lateral Sclerosis in Nordland County, Norway, 2000-2015: prevalence, Incidence, and Clinical Features. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7–8):522–527.
   PubMed Web of Science ®Google Scholar
• Forbes RB, Colville S, Cran GW, et al. Unexpected Decline in Survival from Amyotrophic Lateral Sclerosis/Motor Neurone Disease. J Neurol Neurosurg Psychiatry. 2004;75(12):1753–1755.
   PubMed Web of Science ®Google Scholar
• Daude AC. S. Review of 48 Cases of Motor Neuron Disease at Groote Schuur Hospital: a Pilot Study. J Neurol Stroke. 2017;7:00259.
   Google Scholar
• Paipa AJ, Povedano M, Barcelo a, et al. Survival Benefit of Multidisciplinary Care in Amyotrophic Lateral Sclerosis in Spain: association with Noninvasive Mechanical Ventilation. J Multidiscip Healthc. 2019;12:465–470.
   PubMed Web of Science ®Google Scholar
• Norris F, Shepherd R, Denys E, et al. Onset, Natural History and Outcome in Idiopathic Adult Motor Neuron Disease. J Neurol Sci. 1993;118(1):48–55.
   PubMed Web of Science ®Google Scholar
• Del Aguila MA, Longstreth WT Jr., McGuire V, et al. Prognosis in Amyotrophic Lateral Sclerosis: a Population-Based Study. Neurology. 2003;60(5):813–819.
   PubMed Web of Science ®Google Scholar
• Paulukonis ST, Roberts EM, Valle JP, et al. Survival and Cause of Death among a Cohort of Confirmed Amyotrophic Lateral Sclerosis Cases. PloS One. 2015;10(7):e0131965.
   PubMed Web of Science ®Google Scholar
• Mateen FJ, Carone M, Sorenson EJ. Patients Who Survive 5 Years or More with Als in Olmsted County, 1925-2004. J Neurol Neurosurg Psychiatry. 2010;81(10):1144–1146.
   PubMed Web of Science ®Google Scholar
• Stevic Z, Kostic-Dedic S, Peric S, et al. Prognostic Factors and Survival of Als Patients from Belgrade, Serbia. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(7–8):508–514.
   PubMed Web of Science ®Google Scholar
• Demetriou CA, Hadjivasiliou PM, Kleopa KA, et al. Retrospective Longitudinal Study of Als in Cyprus: clinical Characteristics, Management and Survival. PloS One. 2019;14(9):e0220246.
   PubMed Web of Science ®Google Scholar
• Hardiman O, van den Berg LH, Kiernan MC. Clinical Diagnosis and Management of Amyotrophic Lateral Sclerosis. Nature Reviews Neurology. 2011;7(11):639–649.
   PubMed Web of Science ®Google Scholar
• Elamin M, Bede P, Montuschi a, et al. Predicting Prognosis in Amyotrophic Lateral Sclerosis: a Simple Algorithm. J Neurol. 2015;262(6):1447–1454.
   PubMed Web of Science ®Google Scholar
• Preux PM, Couratier P, Boutros-Toni F, et al. Survival Prediction in Sporadic Amyotrophic Lateral Sclerosis. Age and Clinical Form at Onset Are Independent Risk Factors. Neuroepidemiology. 1996;15(3):153–160.
   PubMed Web of Science ®Google Scholar
• Weil C, Zach N, Rishoni S, et al. Epidemiology of Amyotrophic Lateral Sclerosis: a Population-Based Study in Israel. Neuroepidemiology. 2016;47(2):76–81.
   PubMed Web of Science ®Google Scholar
• Harrison D, Mehta P, van Es MA, et al. “ALS Reversals”: demographics, Disease Characteristics, Treatments, and Co-Morbidities. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7–8):495–499.
   PubMed Web of Science ®Google Scholar
• Vasta R, D’Ovidio F, Canosa a, et al. Plateaus in Amyotrophic Lateral Sclerosis Progression: results from a Population-Based Cohort. Eur J Neurol. 2020. DOI:10.1111/ene.14287.
   PubMedGoogle Scholar
• Bedlack RS, Vaughan T, Wicks P, et al. How Common Are Als Plateaus and Reversals? Neurology. 2016;86(9):808–812.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, et al. The Alsfrs-R: a Revised Als Functional Rating Scale That Incorporates Assessments of Respiratory Function Bdnf Als Study Group (Phase Iii). J Neurol Sci. 1999;169(1–2):13–21.
   PubMed Web of Science ®Google Scholar
• Chio a, Hammond ER, Mora G, et al. Development and Evaluation of a Clinical Staging System for Amyotrophic Lateral Sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):38–44.
   PubMed Web of Science ®Google Scholar
• Roche JC, Rojas-Garcia R, Scott KM, et al. A Proposed Staging System for Amyotrophic Lateral Sclerosis. Brain. 2012;135(3):847–852.
   PubMedGoogle Scholar
• Kimura F, Fujimura C, Ishida S, et al. Progression Rate of Alsfrs-R at Time of Diagnosis Predicts Survival Time in Als. Neurology. 2006;66(2):265–267.
   PubMed Web of Science ®Google Scholar
• Wei Q, Chen X, Zheng Z, et al. The Predictors of Survival in Chinese Amyotrophic Lateral Sclerosis Patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3–4):237–244.
   PubMed Web of Science ®Google Scholar
• Wolf J, Safer a, Wohrle JC, et al. Factors Predicting One-Year Mortality in Amyotrophic Lateral Sclerosis Patients–Data from a Population-Based Registry. BMC Neurol. 2014;14(1):197.
   PubMedGoogle Scholar
• Manera U, Calvo a, Daviddi M, et al. Regional Spreading of Symptoms at Diagnosis as a Prognostic Marker in Amyotrophic Lateral Sclerosis: a Population-Based Study. J Neurol Neurosurg Psychiatry. 2019.
   Web of Science ®Google Scholar
• Baumann F, Henderson RD, Morrison SC, et al. Use of Respiratory Function Tests to Predict Survival in Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler. 2010;1(1–2): 194–202.
   Google Scholar
• Westeneng H-J, Debray TPA, Visser AE, et al. Prognosis for Patients with Amyotrophic Lateral Sclerosis: development and Validation of a Personalised Prediction Model. Lancet Neurol. 2018;17(5): 423–433.
   PubMed Web of Science ®Google Scholar
• Knibb JA, Keren N, Kulka A, et al. A Clinical Tool for Predicting Survival in Als. J Neurol Neurosurg Psychiatry. 2016;87(12):1361–1367.
   PubMed Web of Science ®Google Scholar
• Agosta F, Spinelli EG, Riva N, et al. Survival Prediction Models in Motor Neuron Disease. Eur J Neurol. 2019;26(9):1143–1152.
   PubMed Web of Science ®Google Scholar
• Grollemund V, Pradat PF, Querin G, et al. Machine Learning in Amyotrophic Lateral Sclerosis: achievements, Pitfalls, and Future Directions. Front Neurosci. 2019;13:135.
   PubMed Web of Science ®Google Scholar
• Gomeni R, Fava M. Amyotrophic Lateral Sclerosis Disease Progression Model. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1–2):119–129.
   PubMed Web of Science ®Google Scholar
• Tramacere I, Dalla Bella E, Chio A, et al. The Mitos System Predicts Long-Term Survival in Amyotrophic Lateral Sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(11):1180–1185.
   PubMed Web of Science ®Google Scholar
• Chio A, Logroscino G, Hardiman O, et al. Prognostic Factors in Als: a Critical Review. Amyotroph Lateral Scler. 2009;10(5–6):310–323.
   PubMed Web of Science ®Google Scholar
• Moura MC, Novaes MR, Eduardo EJ, et al. Prognostic Factors in Amyotrophic Lateral Sclerosis: a Population-Based Study. PloS One. 2015;10(10):e0141500.
   PubMed Web of Science ®Google Scholar
• Ngo ST, Steyn FJ, McCombe PA. Body Mass Index and Dietary Intervention: implications for Prognosis of Amyotrophic Lateral Sclerosis. J Neurol Sci. 2014;340(1–2):5–12.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Deng J, Jaffa M, et al. Body Mass Index, Not Dyslipidemia, Is an Independent Predictor of Survival in Amyotrophic Lateral Sclerosis. Muscle Nerve. 2011;44:20–24.
   PubMed Web of Science ®Google Scholar
• Peter RS, Rosenbohm a, Dupuis L, et al. Life Course Body Mass Index and Risk and Prognosis of Amyotrophic Lateral Sclerosis: results from the Als Registry Swabia. Eur J Epidemiol. 2017;32(10):901–908.
   PubMed Web of Science ®Google Scholar
• Moglia C, Calvo a, Grassano M, et al. Early Weight Loss in Amyotrophic Lateral Sclerosis: outcome Relevance and Clinical Correlates in a Population-Based Cohort. J Neurol Neurosurg Psychiatry. 2019;90(6):666–673.
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Faglioni P, Nichelli P, et al. Amyotrophic Lateral Sclerosis: prognostic Indicators of Survival. Amyotroph Lateral Scler. 2006;7(4):211–220.
   PubMedGoogle Scholar
• Calvo a, Canosa a, Bertuzzo D, et al. Influence of Cigarette Smoking on Als Outcome: a Population-Based Study. J Neurol Neurosurg Psychiatry. 2016;87(11):1229–1233.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia Is a Protective Factor in Amyotrophic Lateral Sclerosis. Neurology. 2008;70(13):1004–1009.
   PubMed Web of Science ®Google Scholar
• Dorst J, Kuhnlein P, Hendrich C, et al. Patients with Elevated Triglyceride and Cholesterol Serum Levels Have a Prolonged Survival in Amyotrophic Lateral Sclerosis. J Neurol. 2011;258(4):613–617.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Goetz RR, Rabkin JG, et al. A Prospective Cohort Study of Neuropsychological Test Performance in Als. Amyotroph Lateral Scler. 2010;11(3):312–320.
   PubMed Web of Science ®Google Scholar
• Olney RK, Murphy J, Forshew D, et al. The Effects of Executive and Behavioral Dysfunction on the Course of ALS. Neurology. 2005;65(11):1774–1777.
   PubMed Web of Science ®Google Scholar
• Hayashi N, Atsuta N, Yokoi D, et al. Prognosis of Amyotrophic Lateral Sclerosis Patients Undergoing Tracheostomy Invasive Ventilation Therapy in Japan. J Neurol Neurosurg Psychiatry. 2020;91(3):285–290.
   PubMed Web of Science ®Google Scholar
• Ludolph AC, Dorst J, Dreyhaupt J, et al. Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Ann Neurol. 2020;87(2):206–216.
   PubMed Web of Science ®Google Scholar
• Rooney J, Byrne S, Heverin M, et al. A Multidisciplinary Clinic Approach Improves Survival in Als: a Comparative Study of Als in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry. 2015;86(5):496–501.
   PubMed Web of Science ®Google Scholar
• Trojsi F, Siciliano M, Femiano C, et al. Comorbidity of Dementia with Amyotrophic Lateral Sclerosis (Als): insights from a Large Multicenter Italian Cohort. J Neurol. 2017;264(11):2224–2231.
   PubMed Web of Science ®Google Scholar
• Huynh W, Ahmed R, Mahoney CJ, et al. The Impact of Cognitive and Behavioral Impairment in Amyotrophic Lateral Sclerosis. Expert Rev Neurother. 2020;20(3):281–293.
   PubMed Web of Science ®Google Scholar
• Elamin M, Phukan J, Bede P, et al. Executive Dysfunction Is a Negative Prognostic Indicator in Patients with Als without Dementia. Neurology. 2011;76(14):1263–1269.
   PubMed Web of Science ®Google Scholar
• Bede P, Elamin M, Byrne S, et al. Basal Ganglia Involvement in Amyotrophic Lateral Sclerosis. Neurology. 2013;81(24):2107–2115.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Henderson RD. Effects of Gender in Amyotrophic Lateral Sclerosis. Gend Med. 2010;7(6):557–570.
   PubMedGoogle Scholar
• Longinetti E, Fang F. Epidemiology of Amyotrophic Lateral Sclerosis: an Update of Recent Literature. Curr Opin Neurol. 2019;32(5):771–776.
   PubMed Web of Science ®Google Scholar
• Dorst J, Chen L, Rosenbohm a, et al. Prognostic Factors in Als: a Comparison between Germany and China. J Neurol. 2019;6(6):1516–1525.
   Google Scholar
• Seibold H, Zeileis A, Hothorn T. Individual Treatment Effect Prediction for Amyotrophic Lateral Sclerosis Patients. Stat Methods Med Res. 2018;27(10):3104–3125.
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Malerba SA, Beghi E, et al. Riluzole and Other Prognostic Factors in ALS: a Population-Based Registry Study in Italy. J Neurol. 2018;265:817–827.
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat a, Meurgey JH, et al. Stage at Which Riluzole Treatment Prolongs Survival in Patients with Amyotrophic Lateral Sclerosis: a Retrospective Analysis of Data from a Dose-Ranging Study. Lancet Neurol. 2018;17(5):416–422.
   PubMed Web of Science ®Google Scholar
• Lee CT, Chiu YW, Wang KC, et al. Riluzole and Prognostic Factors in Amyotrophic Lateral Sclerosis Long-Term and Short-Term Survival: a Population-Based Study of 1149 Cases in Taiwan. J Epidemiol. 2013;23:35–40.
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, et al. Confirmatory Double-Blind, Parallel-Group, Placebo-Controlled Study of Efficacy and Safety of Edaravone (Mci-186) in Amyotrophic Lateral Sclerosis Patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7–8):610–617.
   PubMed Web of Science ®Google Scholar
• Shefner J, Heiman-Patterson T, Pioro EP, et al. Long-Term Edaravone Efficacy in Amyotrophic Lateral Sclerosis: post-Hoc Analyses of Study 19 (Mci186-19). Muscle Nerve. 2020;61(2):218–221.
   PubMed Web of Science ®Google Scholar
• Vitacca M, Montini a, Lunetta C, et al. Impact of an Early Respiratory Care Programme with Non-Invasive Ventilation Adaptation in Patients with Amyotrophic Lateral Sclerosis. Eur J Neurol. 2018;25(3):556–e33.
   PubMed Web of Science ®Google Scholar
• Khamankar N, Coan G, Weaver B, et al. Associative Increases in Amyotrophic Lateral Sclerosis Survival Duration with Non-Invasive Ventilation Initiation and Usage Protocols. Front Neurol. 2018;9:578.
   PubMed Web of Science ®Google Scholar
• Bourke SC, Tomlinson M, Williams TL, et al. Effects of Non-Invasive Ventilation on Survival and Quality of Life in Patients with Amyotrophic Lateral Sclerosis: a Randomised Controlled Trial. Lancet Neurol. 2006;5(2):140–147.
   PubMed Web of Science ®Google Scholar
• Sancho J, Martinez D, Bures E, et al. Bulbar Impairment Score and Survival of Stable Amyotrophic Lateral Sclerosis Patients after Noninvasive Ventilation Initiation. ERJ Open Res. 2018;4(2):00159–2017.
   PubMedGoogle Scholar
• Wijesekera LC, Mathers S, Talman P, et al. Natural History and Clinical Features of the Flail Arm and Flail Leg Als Variants. Neurology. 2009;72(12):1087–1094.
   PubMed Web of Science ®Google Scholar
• Turner MR, Faull C, McDermott CJ, et al. Tracheostomy in Motor Neurone Disease. Pract Neurol. 2019;19(6):467–475.
   PubMedGoogle Scholar
• Vianello A, Arcaro G, Palmieri a, et al. Survival and Quality of Life after Tracheostomy for Acute Respiratory Failure in Patients with Amyotrophic Lateral Sclerosis. J Crit Care. 2011;26(329):e7–14.
   Google Scholar
• Traynor BJ, Alexander M, Corr B, et al. Effect of a Multidisciplinary Amyotrophic Lateral Sclerosis (Als) Clinic on Als Survival: a Population Based Study, 1996-2000. J Neurol Neurosurg Psychiatry. 2003;74(9):1258–1261.
   PubMed Web of Science ®Google Scholar
• Czaplinski A, Yen AA, Simpson EP, et al. Slower Disease Progression and Prolonged Survival in Contemporary Patients with Amyotrophic Lateral Sclerosis: is the Natural History of Amyotrophic Lateral Sclerosis Changing? Arch Neurol. 2006;63(8):1139–1143.
   PubMedGoogle Scholar
• Martin S, Trevor-Jones E, Khan S, et al. The Benefit of Evolving Multidisciplinary Care in ALS: A Diagnostic Cohort Survival Comparison. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7–8):569–575.
   PubMed Web of Science ®Google Scholar
• Kim WK, Liu X, Sandner J, et al. Study of 962 Patients Indicates Progressive Muscular Atrophy Is a Form of ALS. Neurology. 2009;73(20):1686–1692.
   PubMed Web of Science ®Google Scholar
• Van den Berg-vos R, Visser J, Kalmijn S, et al. A Long-Term Prospective Study of the Natural Course of Sporadic Adult-Onset Lower Motor Neuron Syndromes. Arch Neurol. 2009;66(6):751–757.
   PubMedGoogle Scholar
• Tartaglia MC, Rowe a, Findlater K, et al. Differentiation between Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis: examination of Symptoms and Signs at Disease Onset and During Follow-Up. Arch Neurol. 2007;64(2):232–236.
   PubMedGoogle Scholar
• Kuipers-Upmeijer J, de Jager AE, Hew JM, et al. Primary Lateral Sclerosis: clinical, Neurophysiological, and Magnetic Resonance Findings. J Neurol Neurosurg Psychiatry. 2001;71(5):615–620.
   PubMed Web of Science ®Google Scholar
• Turner MR, Barohn RJ, Corcia P, et al. Primary Lateral Sclerosis: consensus Diagnostic Criteria. J Neurol Neurosurg Psychiatry. 2020;91(4):373–377.
   Web of Science ®Google Scholar
• Menon P, Geevasinga N, Yiannikas C, et al. Sensitivity and Specificity of Threshold Tracking Transcranial Magnetic Stimulation for Diagnosis of Amyotrophic Lateral Sclerosis: a Prospective Study. Lancet Neurol. 2015;14(5):478–484.
   PubMed Web of Science ®Google Scholar
• de Vries BS, Rustemeijer LMM, Bakker LA, et al. Cognitive and Behavioural Changes in PLS and PMA: challenging the Concept of Restricted Phenotypes. J Neurol Neurosurg Psychiatry. 2019;90(2):141–147.
   PubMed Web of Science ®Google Scholar
• Finegan E, Li Hi Shing S, Chipika RH, et al. Widespread Subcortical Grey Matter Degeneration in Primary Lateral Sclerosis: a Multimodal Imaging Study with Genetic Profiling. NeuroImage: Clinical. 2019;24:102089.
   PubMed Web of Science ®Google Scholar
• Soraru G, Ermani M, Logroscino G, et al. Natural History of Upper Motor Neuron-Dominant Als. Amyotroph Lateral Scler. 2010;11(5):424–429.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheng B, Katz IB, et al. The Natural History of Primary Lateral Sclerosis. Neurology. 2006;66(5):647–653.
   PubMed Web of Science ®Google Scholar
• Soraru G, D’Ascenzo C, Nicolao P, et al. Muscle Histopathology in Upper Motor Neuron-Dominant Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler. 2008;9(5):287–293.
   PubMed Web of Science ®Google Scholar
• Baumann F, Henderson RD, Ridall PG, et al. Use of Bayesian Mune to Show Differing Rate of Loss of Motor Units in Subgroups of Als. Clin Neurophysiol. 2012;123(12):2446–2453.
   PubMed Web of Science ®Google Scholar
• Hu MT, Ellis CM, Al-Chalabi A, et al. Flail Arm Syndrome: a Distinctive Variant of Amyotrophic Lateral Sclerosis. J Neurol Neurosurg Psychiatry. 1998;65(6):950–951.
   PubMed Web of Science ®Google Scholar
• Talman P, Forbes A, Mathers S. Clinical Phenotypes and Natural Progression for Motor Neuron Disease: analysis from an Australian Database. Amyotroph Lateral Scler. 2009;10(2):79–84.
   PubMed Web of Science ®Google Scholar
• Moglia C, Calvo A, Canosa A, et al. Influence of Arterial Hypertension, Type 2 Diabetes and Cardiovascular Risk Factors on Als Outcome: a Population-Based Study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7–8):590–597.
   PubMed Web of Science ®Google Scholar
• Lekoubou A, Matsha TE, Sobngwi E, et al. Effects of Diabetes Mellitus on Amyotrophic Lateral Sclerosis: a Systematic Review. BMC Res Notes. 2014;7(1):171.
   PubMedGoogle Scholar
• Mandrioli J, Ferri L, Fasano A, et al. Cardiovascular Diseases May Play a Negative Role in the Prognosis of Amyotrophic Lateral Sclerosis. Eur J Neurol. 2018;25(6):861–868.
   PubMed Web of Science ®Google Scholar
• Diekmann K, Kuzma-Kozakiewicz M, Piotrkiewicz M, et al. Impact of Comorbidities and Co-Medication on Disease Onset and Progression in a Large German Als Patient Group. J Neurol. 2020. DOI:10.1007/s00415-020-09799-z.
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Lash TL. Statins and Amyotrophic Lateral Sclerosis–the Level of Evidence for an Association. J Intern Med. 2009;266(6):520–526.
   PubMed Web of Science ®Google Scholar
• Turner RM, Pirmohamed M. Statin-Related Myotoxicity: a Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. J Clin Med. 2019;9(1):22.
   PubMed Web of Science ®Google Scholar
• Cetin H, Klickovic U, Rath J, et al. Associations between Co-Medications and Survival in Als-a Cohort Study from Austria. J Neurol. 2015;262(7):1698–1705.
   PubMed Web of Science ®Google Scholar
• Xie Y, Bowe B, Li T, et al. Risk of Death among Users of Proton Pump Inhibitors: a Longitudinal Observational Cohort Study of United States Veterans. BMJ Open. 2017;7(6):e015735.
   PubMed Web of Science ®Google Scholar
• Bruno G, Zaccari P, Rocco G, et al. Proton Pump Inhibitors and Dysbiosis: current Knowledge and Aspects to Be Clarified. World J Gastroenterol. 2019;25(22):2706–2719.
   PubMed Web of Science ®Google Scholar
• Verber NS, Shepheard SR, Sassani M, et al. Biomarkers in Motor Neuron Disease: a State of the Art Review. Front Neurol. 2019;10:291.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Pfluger C, Singh P, et al. Serial Measurements of Phosphorylated Neurofilament-Heavy in the Serum of Subjects with Amyotrophic Lateral Sclerosis. J Neurol Sci. 2015;353(1–2):122–129.
   PubMed Web of Science ®Google Scholar
• Rafiq MK, Lee E, Bradburn M, et al. Creatine Kinase Enzyme Level Correlates Positively with Serum Creatinine and Lean Body Mass, and Is a Prognostic Factor for Survival in Amyotrophic Lateral Sclerosis. Eur J Neurol. 2016;23(6):1071–1078.
   PubMed Web of Science ®Google Scholar
• Sumien N, Shetty RA, Gonzales EB. Creatine, Creatine Kinase, and Aging. Subcell Biochem. 2018;90:145–168.
   PubMedGoogle Scholar
• Chiò a, Calvo a, Bovio G, et al. Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and Creatinine: a Population-Based Study. JAMA Neurol. 2014;71(9):1134–1142.
   PubMed Web of Science ®Google Scholar
• Xu Z, Henderson RD, David M, et al. Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: a Systematic Review and Meta-Analysis. PloS One. 2016;11(10):e0164625.
   PubMed Web of Science ®Google Scholar
• Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament Light Chain: a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. Neurology. 2015;84(22):2247–2257.
   PubMed Web of Science ®Google Scholar
• Boylan KB, Glass JD, Crook JE, et al. Phosphorylated Neurofilament Heavy Subunit (Pnf-H) in Peripheral Blood and Csf as a Potential Prognostic Biomarker in Amyotrophic Lateral Sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(4):467–472.
   PubMed Web of Science ®Google Scholar
• Shepheard SR, Wuu J, Cardoso M, et al. Urinary p75 ECD. Neurology. 2017;88(12):1137–1143.
   PubMed Web of Science ®Google Scholar
• Fabbrini E, Serafini M, Colic Baric I, et al. Effect of Plasma Uric Acid on Antioxidant Capacity, Oxidative Stress, and Insulin Sensitivity in Obese Subjects. Diabetes. 2014;63(3):976–981.
   PubMed Web of Science ®Google Scholar
• Abraham a, Drory VE. Influence of Serum Uric Acid Levels on Prognosis and Survival in Amyotrophic Lateral Sclerosis: a Meta-Analysis. J Neurol. 2014;261(6):1133–1138.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Nicholson K, Chan J, et al. Urate Levels Predict Survival in Amyotrophic Lateral Sclerosis: analysis of the Expanded Pooled Resource Open-Access Als Clinical Trials Database. Muscle Nerve. 2018;57(3):430–434.
   PubMed Web of Science ®Google Scholar
• Xu Z, Lee A, Nouwens a, et al. Mass Spectrometry Analysis of Plasma from Amyotrophic Lateral Sclerosis and Control Subjects. Amyotroph Lateral Scler Frontotemporal Degener. 201819(5–6);362–376.
   PubMed Web of Science ®Google Scholar
• Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and Clinical Significance. JPEN J Parenter Enteral Nutr. 2019;43(2):181–193.
   PubMed Web of Science ®Google Scholar
• Lunetta C, Lizio A, Maestri E, et al. Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2017;74(6):660–667.
   PubMed Web of Science ®Google Scholar
• Wilson ME, Boumaza I, Lacomis D, et al. Cystatin C: a Candidate Biomarker for Amyotrophic Lateral Sclerosis. PloS One. 2010;5(12):e15133.
   PubMed Web of Science ®Google Scholar
• Ngo ST, Steyn FJ, Huang L, et al. Altered Expression of Metabolic Proteins and Adipokines in Patients with Amyotrophic Lateral Sclerosis. J Neurol Sci. 2015;357(1–2):22–27.
   PubMed Web of Science ®Google Scholar
• Pronto-Laborinho A, Pinto S, Gromicho M, et al. Interleukin-6 and Amyotrophic Lateral Sclerosis. J Neurol Sci. 2019;398:50–53.
   PubMed Web of Science ®Google Scholar
• Rosenbohm a, Nagel G, Peter RS, et al. Association of Serum Retinol-Binding Protein 4 Concentration with Risk for and Prognosis of Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018;75(5):600–607.
   PubMed Web of Science ®Google Scholar
• Nagel G, Peter RS, Rosenbohm a, et al. Association of Insulin-Like Growth Factor 1 Concentrations with Risk for and Prognosis of Amyotrophic Lateral Sclerosis - Results from the Als Registry Swabia. Sci Rep. 2020;10(1):736.
   PubMed Web of Science ®Google Scholar
• Lepore AC, Haenggeli C, Gasmi M, et al. Intraparenchymal Spinal Cord Delivery of Adeno-Associated Virus Igf-1 Is Protective in the SOD1G93A Model of ALS. Brain Res. 2007;1185:256–265.
   PubMed Web of Science ®Google Scholar
• Dodge JC, Treleaven CM, Fidler JA, et al. Aav4-Mediated Expression of Igf-1 and Vegf within Cellular Components of the Ventricular System Improves Survival Outcome in Familial Als Mice. Mol Ther. 2010;18(12):2075–2084.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Lee JD, Woodruff TM, et al. The Peripheral Immune System and Amyotrophic Lateral Sclerosis. Front Neurol. 2020;11(279). DOI:10.3389/fneur.2020.00279.
   Google Scholar
• Murdock BJ, Zhou T, Kashlan SR, et al. Correlation of Peripheral Immunity with Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurol. 2017;74(12):1446–1454.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Hong YH, Kim SM, et al. High Neutrophil-to-Lymphocyte Ratio Predicts Short Survival Duration in Amyotrophic Lateral Sclerosis. Sci Rep. 2020;10(1):428.
   PubMed Web of Science ®Google Scholar
• Henkel JS, Beers DR, Wen S, et al. Regulatory T-Lymphocytes Mediate Amyotrophic Lateral Sclerosis Progression and Survival. EMBO Mol Med. 2013;5(1):64–79.
   PubMed Web of Science ®Google Scholar
• Sheean RK, McKay FC, Cretney E, et al. Association of Regulatory T-Cell Expansion with Progression of Amyotrophic Lateral Sclerosis: a Study of Humans and a Transgenic Mouse Model. JAMA Neurol. 2018;75(6):681–689.
   PubMed Web of Science ®Google Scholar
• Zhang R, Gascon R, Miller RG, et al. Evidence for Systemic Immune System Alterations in Sporadic Amyotrophic Lateral Sclerosis (Sals). J Neuroimmunol. 2005;159(1–2):215–224.
   PubMed Web of Science ®Google Scholar
• Henderson RD, McCombe PA. Assessment of Motor Units in Neuromuscular Disease. Neurotherapeutics. 2017;14(1):69–77.
   PubMed Web of Science ®Google Scholar
• Armon C, Brandstater ME. Motor Unit Number Estimate-Based Rates of Progression of Als Predict Patient Survival. Muscle Nerve. 1999;22(11):1571–1575.
   PubMed Web of Science ®Google Scholar
• Neuwirth C, Nandedkar S, Stalberg E, et al. Motor Unit Number Index (Munix): a Novel Neurophysiological Marker for Neuromuscular Disorders; Test-Retest Reliability in Healthy Volunteers. Clin Neurophysiol. 2011;122(9):1867–1872.
   PubMed Web of Science ®Google Scholar
• Wilbourn AJ. The “Split Hand Syndrome”. Muscle Nerve. 2000;23(1):138.
   PubMed Web of Science ®Google Scholar
• Rutkove SB, Caress JB, Cartwright MS, et al. Electrical Impedance Myography as a Biomarker to Assess Als Progression. Amyotroph Lateral Scler. 2012;13(5):439–445.
   PubMed Web of Science ®Google Scholar
• Vucic S, Rutkove SB. Neurophysiological Biomarkers in Amyotrophic Lateral Sclerosis. Curr Opin Neurol. 2018;31(5):640–647.
   PubMed Web of Science ®Google Scholar
• Huynh W, Dharmadasa T, Vucic S, et al. Functional Biomarkers for Amyotrophic Lateral Sclerosis. Front Neurol. 2018;9:1141.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Simon NG, Geevasinga N, et al. The Evolution of Motor Cortical Dysfunction in Amyotrophic Lateral Sclerosis. Clin Neurophysiol. 2017;128(6):1075–1082.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Park SB, Geevasinga N, et al. Motor Cortical Function Determines Prognosis in Sporadic Als. Neurology. 2016;87(5):513–520.
   PubMed Web of Science ®Google Scholar
• Chew S, Atassi N. Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis. Front Neurol. 2019;10:135.
   PubMed Web of Science ®Google Scholar
• Barnes SL, Simon NG. Clinical and Research Applications of Neuromuscular Ultrasound in Amyotrophic Lateral Sclerosis. Degener Neurol Neuromuscul Dis. 2019;9:89–102.
   PubMed Web of Science ®Google Scholar
• Agosta F, Pagani E, Petrolini M, et al. Assessment of White Matter Tract Damage in Patients with Amyotrophic Lateral Sclerosis: a Diffusion Tensor Mr Imaging Tractography Study. AJNR Am J Neuroradiol. 2010;31(8):1457–1461.
   PubMed Web of Science ®Google Scholar
• Cirillo M, Esposito F, Tedeschi G, et al. Widespread Microstructural White Matter Involvement in Amyotrophic Lateral Sclerosis: a Whole-Brain Dti Study. AJNR Am J Neuroradiol. 2012;33(6):1102–1108.
   PubMed Web of Science ®Google Scholar
• Bede P, Hardiman O. Longitudinal Structural Changes in Als: a Three Time-Point Imaging Study of White and Gray Matter Degeneration. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3–4):232–241.
   PubMed Web of Science ®Google Scholar
• Menke RA, Korner S, Filippini N, et al. Widespread Grey Matter Pathology Dominates the Longitudinal Cerebral MRI and Clinical Landscape of Amyotrophic Lateral Sclerosis. Brain. 2014;137(9):2546–2555.
   PubMedGoogle Scholar
• Schuster C, Hardiman O, Bede P. Survival Prediction in Amyotrophic Lateral Sclerosis Based on Mri Measures and Clinical Characteristics. BMC Neurol. 2017;17(1):73.
   PubMed Web of Science ®Google Scholar
• van der Burgh HK, Schmidt R, Westeneng HJ, et al. Deep Learning Predictions of Survival Based on Mri in Amyotrophic Lateral Sclerosis. Neuroimage Clin. 2017;13:361–369.
   PubMed Web of Science ®Google Scholar
• Marin B, Boumediene F, Logroscino G, et al. Variation in Worldwide Incidence of Amyotrophic Lateral Sclerosis: a Meta-Analysis. Int J Epidemiol. 2017;46(1):57–74.
   PubMed Web of Science ®Google Scholar
• Xu L, Liu T, Liu L, et al. Global Variation in Prevalence and Incidence of Amyotrophic Lateral Sclerosis: a Systematic Review and Meta-Analysis. J Neurol. 2020;267:944-53.
   Web of Science ®Google Scholar
• Logroscino G, Piccininni M. Amyotrophic Lateral Sclerosis Descriptive Epidemiology: the Origin of Geographic Difference. Neuroepidemiology. 2019;52(1–2):93–103.
   PubMed Web of Science ®Google Scholar
• Zou ZY, Zhou ZR, Che CH, et al. Genetic Epidemiology of Amyotrophic Lateral Sclerosis: a Systematic Review and Meta-Analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540–549.
   PubMed Web of Science ®Google Scholar
• Chio a, Calvo a, Moglia C, et al. Atxn2 Polyq Intermediate Repeats Are a Modifier of Als Survival. Neurology. 2015;84(3):251–258.
   PubMed Web of Science ®Google Scholar
• Borghero G, Pugliatti M, Marrosu F, et al. Atxn2 Is a Modifier of Phenotype in Als Patients of Sardinian Ancestry. Neurobiol Aging. 2015;36(2906):e1–5.
   PubMedGoogle Scholar
• Cronin S, Hardiman O, Traynor BJ. Ethnic Variation in the Incidence of Als: a Systematic Review. Neurology. 2007;68(13):1002–1007.
   PubMed Web of Science ®Google Scholar
• Rechtman L, Jordan H, Wagner L, et al. Racial and Ethnic Differences among Amyotrophic Lateral Sclerosis Cases in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(65–71):65–71.
   PubMedGoogle Scholar
• Roberts AL, Johnson NJ, Chen JT, et al. Race/Ethnicity, Socioeconomic Status, and Als Mortality in the United States. Neurology. 2016;87(22):2300–2308.
   PubMed Web of Science ®Google Scholar
• Moura MC, Casulari LA, Carvalho Garbi Novaes MR. Ethnic and Demographic Incidence of Amyotrophic Lateral Sclerosis (Als) in Brazil: a Population Based Study. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3–4):275–281.
   PubMed Web of Science ®Google Scholar
• Pliner HA, Mann DM, Traynor BJ. Searching for Grendel: origin and Global Spread of the C9orf72 Repeat Expansion. Acta Neuropathol. 2014;127(3):391–396.
   PubMed Web of Science ®Google Scholar
• Marin B, Logroscino G, Boumediene F, et al. Clinical and Demographic Factors and Outcome of Amyotrophic Lateral Sclerosis in Relation to Population Ancestral Origin. Eur J Epidemiol. 2016;31(3):229–245.
   PubMed Web of Science ®Google Scholar
• Kacem I, Sghaier I, Bougatef S, et al. Epidemiological and Clinical Features of Amyotrophic Lateral Sclerosis in a Tunisian Cohort. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:131-9.
   PubMedGoogle Scholar
• Luna J, Diagana M, Ait Aissa L, et al. Clinical Features and Prognosis of Amyotrophic Lateral Sclerosis in Africa: the Tropals Study. J Neurol Neurosurg Psychiatry. 2019;90(1):20–29.
   PubMed Web of Science ®Google Scholar
• Arthur KC, Calvo a, Price TR, et al. Projected Increase in Amyotrophic Lateral Sclerosis from 2015 to 2040. Nat Commun. 2016;7(1):12408.
   PubMedGoogle Scholar
• Bali T, Self W, Liu J, et al. Defining Sod1 Als Natural History to Guide Therapeutic Clinical Trial Design. J Neurol Neurosurg Psychiatry. 2017;88(2):99–105.
   PubMed Web of Science ®Google Scholar
• Millecamps S, Salachas F, Cazeneuve C, et al. Sod1, Ang, Vapb, Tardbp, and Fus Mutations in Familial Amyotrophic Lateral Sclerosis: genotype-Phenotype Correlations. J Med Genet. 2010;47(8):554–560.
   PubMed Web of Science ®Google Scholar
• Naumann M, Peikert K, Gunther R, et al. Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2019;6(12):2384–2394.
   PubMedGoogle Scholar
• Van Mossevelde S, van der Zee J, Gijselinck I, et al. Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Brain. 2016;139(2):452–467.
   PubMed Web of Science ®Google Scholar
• Pang SY, Hsu JS, Teo KC, et al. Burden of Rare Variants in Als Genes Influences Survival in Familial and Sporadic Als. Neurobiol Aging. 2017;58(238):e9–.e15.
   Google Scholar
• Vidal-Taboada JM, Lopez-Lopez A, Salvado M, et al. Unc13a Confers Risk for Sporadic Als and Influences Survival in a Spanish Cohort. J Neurol. 2015;262(10):2285–2292.
   PubMed Web of Science ®Google Scholar
• Van Hoecke A, Schoonaert L, Lemmens R, et al. Epha4 Is a Disease Modifier of Amyotrophic Lateral Sclerosis in Animal Models and in Humans. Nat Med. 2012;18(9):1418–1422.
   PubMed Web of Science ®Google Scholar
• Yu CJ, Wang L, Mao SL, et al. The Clinical Assessment of Amyotrophic Lateral Sclerosis Patients’ Prognosis by Znf512b Gene, Neck Flexor Muscle Power Score and Body Mass Index (Bmi). BMC Neurol. 2018;18(1):211.
   PubMedGoogle Scholar
• Iida A, Takahashi a, Kubo M, et al. A Functional Variant in Znf512b Is Associated with Susceptibility to Amyotrophic Lateral Sclerosis in Japanese. Hum Mol Genet. 2011;20(18):3684–3692.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez A, Gamez J, Syriani E, et al. Cx3cr1 Is a Modifying Gene of Survival and Progression in Amyotrophic Lateral Sclerosis. PloS One. 2014;9(5):e96528.
   PubMed Web of Science ®Google Scholar
• Nandar W, Neely EB, Simmons Z, et al. H63d Hfe Genotype Accelerates Disease Progression in Animal Models of Amyotrophic Lateral Sclerosis. Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease. 2014;1842(12):2413–2426.
   PubMed Web of Science ®Google Scholar
• Chio A, Mora G, Sabatelli M, et al. Hfe P.H63d Polymorphism Does Not Influence Als Phenotype and Survival. Neurobiol Aging. 2015;36(2906):e7–11.
   Google Scholar
• Wosiski-Kuhn M, Robinson M, Strupe J, et al. IL6 receptor 358 Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e631.
   PubMed Web of Science ®Google Scholar
• Glasmacher SA, Wong C, Pearson IE et al. Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: a Systematic Review and Meta-Analysis. JAMA Neurol. 2019;77:367-376.
   Web of Science ®Google Scholar
• Cammack AJ, Atassi N, Hyman T, et al. Prospective Natural History Study of C9orf72 Als Clinical Characteristics and Biomarkers. Neurology. 2019;93(17):e1605–e17.
   PubMed Web of Science ®Google Scholar
• Zou ZY, Peng Y, Wang XN, et al. Screening of the Tardbp Gene in Familial and Sporadic Amyotrophic Lateral Sclerosis Patients of Chinese Origin. Neurobiol Aging. 2012;33(2229):e11–.e18.
   Google Scholar
• Ye CH, Lu XL, Zheng MY, et al. Absence of Mutations in Exon 6 of the Tardbp Gene in 207 Chinese Patients with Sporadic Amyotrohic Lateral Sclerosis. PloS One. 2013;8(7):e68106.
   PubMed Web of Science ®Google Scholar
• Fogh I, Lin K, Tiloca C, et al. Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurol. 2016;73(7):812–820.
   PubMed Web of Science ®Google Scholar
• Chio A, Mora G, Restagno G, et al. Unc13a Influences Survival in Italian Amyotrophic Lateral Sclerosis Patients: a Population-Based Study. Neurobiol Aging. 2013;34(357):e1–5.
   PubMedGoogle Scholar
• Gaastra B, Shatunov A, Pulit S, et al. Rare Genetic Variation in Unc13a May Modify Survival in Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(7–8):593–599.
   PubMed Web of Science ®Google Scholar
• Diekstra FP, van Vught PW, van Rheenen W, et al. Unc13a Is a Modifier of Survival in Amyotrophic Lateral Sclerosis. Neurobiol Aging. 2012;33(630):e3–8.
   PubMedGoogle Scholar
• Landers JE, Melki J, Meininger V et al. Reduced Expression of the Kinesin-Associated Protein 3 (Kifap3) Gene Increases Survival in Sporadic Amyotrophic Lateral Sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 106, 9004–9009 (2009).
   Google Scholar
• Traynor BJ, Nalls M, Lai SL et al. Kinesin-Associated Protein 3 (Kifap3) Has No Effect on Survival in a Population-Based Cohort of Als Patients. Proceedings of the National Academy of Sciences of the United States of America, 107, 12335–12338 (2010).
   Google Scholar
• van Doormaal PT, Ticozzi N, Gellera C, et al. Analysis of the Kifap3 Gene in Amyotrophic Lateral Sclerosis: a Multicenter Survival Study. Neurobiol Aging. 2014;35(2420):e13–4.
   Google Scholar
• Hannan AJ. Tandem Repeats Mediating Genetic Plasticity in Health and Disease. Nature Reviews Genetics. 2018;19(5):286–298.
   PubMed Web of Science ®Google Scholar
• Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 Intermediate-Length Polyglutamine Expansions Are Associated with Increased Risk for Als. Nature. 2010;466(7310):1069–1075.
   PubMed Web of Science ®Google Scholar
• Sproviero W, Shatunov a, Stahl D, et al. Atxn2 Trinucleotide Repeat Length Correlates with Risk of Als. Neurobiol Aging. 2017;51(178):e1–.e9.
   PubMedGoogle Scholar
• Labat-Robert J, Robert L. Longevity and Aging. Mechanisms and Perspectives. Pathologie-biologie. 2015;63(6):272–276.
   PubMedGoogle Scholar
• Ribeiro AI, Krainski ET, Carvalho MS, et al. Where Do People Live Longer and Shorter Lives? An Ecological Study of Old-Age Survival across 4404 Small Areas from 18 European Countries. J Epidemiol Community Health. 2016;70(6):561–568.
   PubMed Web of Science ®Google Scholar
• Ragagnin AMG, Shadfar S, Vidal M, et al. Motor Neuron Susceptibility in Als/Ftd. Front Neurosci. 2019;13:532.
   PubMed Web of Science ®Google Scholar
• Kole AJ, Annis RP, Mature Neurons: DM. Equipped for Survival. Cell Death Dis. 2013;4(6):e689.
   PubMedGoogle Scholar
• Nijssen J, Comley LH, Hedlund E. Motor Neuron Vulnerability and Resistance in Amyotrophic Lateral Sclerosis. Acta Neuropathol. 2017;133(6):863–885.
   PubMed Web of Science ®Google Scholar
• Mannen T, Iwata M, Toyokura Y, et al. The Onuf’s Nucleus and the External Anal Sphincter Muscles in Amyotrophic Lateral Sclerosis and Shy-Drager Syndrome. Acta Neuropathol. 1982;58(4):255–260.
   PubMed Web of Science ®Google Scholar
• Birger A, Ottolenghi M, Perez L, et al. Als-Related Human Cortical and Motor Neurons Survival Is Differentially Affected by Sema3a. Cell Death Dis. 2018;9(3):256.
   PubMedGoogle Scholar
• Almeida A. Genetic Determinants of Neuronal Vulnerability to Apoptosis. Cell Mol Life Sci. 2013;70(1):71–88.
   PubMed Web of Science ®Google Scholar
• Pfisterer U, Khodosevich K. Neuronal Survival in the Brain: neuron Type-Specific Mechanisms. Cell Death Dis. 2017;8(3):e2643.
   PubMedGoogle Scholar
• Ravits J. Focality, Stochasticity and Neuroanatomic Propagation in Als Pathogenesis. Exp Neurol. 2014;262(Pt B):121–126.
   PubMedGoogle Scholar
• Burrell JR, Vucic S, Kiernan MC. Isolated Bulbar Phenotype of Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler. 2011;12(4):283–289.
   PubMed Web of Science ®Google Scholar
• Zhang HG, Chen L, Tang L, et al. Clinical Features of Isolated Bulbar Palsy of Amyotrophic Lateral Sclerosis in Chinese Population. Chin Med J (Engl). 2017;130(15):1768–1772.
   PubMed Web of Science ®Google Scholar
• Kanouchi T, Ohkubo T, Yokota T. Can Regional Spreading of Amyotrophic Lateral Sclerosis Motor Symptoms Be Explained by Prion-Like Propagation? J Neurol Neurosurg Psychiatry. 2012;83(7):739–745.
   PubMed Web of Science ®Google Scholar
• Nussbaum-Krammer CI, Park KW, Li L, et al. Spreading of a Prion Domain from Cell-to-Cell by Vesicular Transport in Caenorhabditis Elegans. PLoS Genet. 2013;9(3):e1003351.
   PubMed Web of Science ®Google Scholar
• McAlary L, Plotkin SS, Yerbury JJ, et al. Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis. Front Mol Neurosci. 2019;12:262.
   PubMed Web of Science ®Google Scholar
• Schwartz M, Kipnis J. Protective Autoimmunity and Neuroprotection in Inflammatory and Noninflammatory Neurodegenerative Diseases. J Neurol Sci. 2005;233(1–2):163–166.
   PubMed Web of Science ®Google Scholar
• Misra MK, Damotte V, Hollenbach JA. The Immunogenetics of Neurological Disease. Immunology. 2018;153(4):399–414.
   PubMed Web of Science ®Google Scholar
• Mosaad YM. Clinical Role of Human Leukocyte Antigen in Health and Disease. Scand J Immunol. 2015;82(4):283–306.
   PubMed Web of Science ®Google Scholar
• Behan PO, Dick HM, Durward WF. Histocompatibility Antigens Associated with Motor Neurone Disease. J Neurol Sci. 1977;32(2):213–217.
   PubMed Web of Science ®Google Scholar
• Kott E, Livni E, Zamir R, et al. Cell-Mediated Immunity to Polio and Hla Antigens in Amyotrophic Lateral Sclerosis. Neurology. 1979;29(7):1040–1044.
   PubMed Web of Science ®Google Scholar
• Antel JP, Arnason BG, Fuller TC, et al. Histocompatibility Typing in Amyotrophic Lateral Sclerosis. Arch Neurol. 1976;33(6):423–425.
   PubMedGoogle Scholar
• Goodall EF, Greenway MJ, van Marion I, et al. Association of the H63d Polymorphism in the Hemochromatosis Gene with Sporadic Als. Neurology. 2005;65(6):934–937.
   PubMed Web of Science ®Google Scholar
• Li M, Wang L, Wang W, et al. Mutations in the Hfe Gene and Sporadic Amyotrophic Lateral Sclerosis Risk: a Meta-Analysis of Observational Studies. Braz J Med Biol Res. 2014;47(3):215–222.
   PubMed Web of Science ®Google Scholar
• Sutedja NA, Sinke RJ, Van Vught PW, et al. The Association between H63d Mutations in Hfe and Amyotrophic Lateral Sclerosis in a Dutch Population. Arch Neurol. 2007;64(1):63–67.
   PubMedGoogle Scholar
• Song S, Miranda CJ, Braun L, et al. Major Histocompatibility Complex Class I Molecules Protect Motor Neurons from Astrocyte-Induced Toxicity in Amyotrophic Lateral Sclerosis. Nat Med. 2016;22(4):397–403.
   PubMed Web of Science ®Google Scholar
• Hu Y, Cao C, Qin XY, et al. Increased Peripheral Blood Inflammatory Cytokine Levels in Amyotrophic Lateral Sclerosis: a Meta-Analysis Study. Sci Rep. 2017;7(1):9094.
   PubMed Web of Science ®Google Scholar
• Ehrhart J, Smith AJ, Kuzmin-Nichols N, et al. Humoral Factors in Als Patients During Disease Progression. J Neuroinflammation. 2015;12(1):127.
   PubMedGoogle Scholar
• Cajado C, Cerqueira BA, Couto FD, et al. TNF-alpha and IL-8: serum levels and gene polymorphisms (−308G>a and −251A>T) are associated with classical biomarkers and medical history in children with sickle cell anemia. Cytokine. 2011;56(2):312–317.
   PubMed Web of Science ®Google Scholar
• Wang Y, Duan W, Wang W, et al. Scaav9-Vegf Prolongs the Survival of Transgenic Als Mice by Promoting Activation of M2 Microglia and the Pi3k/Akt Pathway. Brain Res. 2016;1648:1–10.
   PubMed Web of Science ®Google Scholar
• Wei ZH, Li YY, Huang SQ, et al. Genetic Variants in Il-33/St2 Pathway with the Susceptibility to Hepatocellular Carcinoma in a Chinese Population. Cytokine. 2019;118:124-9.
   Web of Science ®Google Scholar
• Camandola S, Mattson MP. Nf-Kappa B as a Therapeutic Target in Neurodegenerative Diseases. Expert Opin Ther Targets. 2007;11(2):123–132.
   PubMed Web of Science ®Google Scholar
• Maruyama H, Morino H, Ito H, et al. Mutations of Optineurin in Amyotrophic Lateral Sclerosis. Nature. 2010;465(7295):223–226.
   PubMed Web of Science ®Google Scholar
• Swarup V, Phaneuf D, Dupre N, et al. Deregulation of Tdp-43 in Amyotrophic Lateral Sclerosis Triggers Nuclear Factor Kappab-Mediated Pathogenic Pathways. J Exp Med. 2011;208(12):2429–2447.
   PubMed Web of Science ®Google Scholar
• Vandoorne T, De Bock K, Van Den Bosch L. Energy Metabolism in Als: an Underappreciated Opportunity? Acta Neuropathol. 2018;135(4):489–509.
   PubMed Web of Science ®Google Scholar
• Steyn FJ, Ioannides ZA, van Eijk RPA, et al. Hypermetabolism in ALS Is Associated with Greater Functional Decline and Shorter Survival. J Neurol Neurosurg Psychiatry. 2018;89(10):1016–1023.
   PubMed Web of Science ®Google Scholar
• Kastenmuller G, Raffler J, Gieger C, et al. Genetics of Human Metabolism: an Update. Hum Mol Genet. 2015;24(R1):R93–R101.
   PubMedGoogle Scholar
• Mouzat K, Molinari N, Kantar J, et al. Liver X Receptor Genes Variants Modulate Als Phenotype. Mol Neurobiol. 2018;55(3):1959–1965.
   PubMed Web of Science ®Google Scholar
• Napoli JL. Functions of Intracellular Retinoid Binding-Proteins. Subcell Biochem. 2016;81:21–76.
   PubMedGoogle Scholar
• Kovacs P, Geyer M, Berndt J, et al. Effects of Genetic Variation in the Human Retinol Binding Protein-4 Gene (Rbp4) on Insulin Resistance and Fat Depot-Specific mRNA Expression. Diabetes. 2007;56(12):3095–3100.
   PubMed Web of Science ®Google Scholar
• Chae YJ, Chung CE, Kim BJ, et al. The Gene Encoding Guanidinoacetate Methyltransferase (Gamt) Maps to Human Chromosome 19 at Band P13.3 and to Mouse Chromosome 10. Genomics. 1998;49(1):162–164.
   PubMed Web of Science ®Google Scholar
• Pansarasa O, Rossi D, Berardinelli a, et al. Amyotrophic Lateral Sclerosis and Skeletal Muscle: an Update. Mol Neurobiol. 2014;49(2):984–990.
   PubMed Web of Science ®Google Scholar
• Scott W, Stevens J, Binder-Macleod SA. Human Skeletal Muscle Fiber Type Classifications. Phys Ther. 2001;81(11):1810–1816.
   PubMed Web of Science ®Google Scholar
• Simoneau JA, Bouchard C. Genetic Determinism of Fiber Type Proportion in Human Skeletal Muscle. Faseb J. 1995;9(11):1091–1095.
   PubMed Web of Science ®Google Scholar
• Ahmetov II, Vinogradova OL, Williams AG. Gene Polymorphisms and Fiber-Type Composition of Human Skeletal Muscle. Int J Sport Nutr Exerc Metab. 2012;22(4):292–303.
   PubMed Web of Science ®Google Scholar
• Harwood CA, Westgate K, Gunstone S, et al. Long-Term Physical Activity: an Exogenous Risk Factor for Sporadic Amyotrophic Lateral Sclerosis? Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(5–6):377–384.
   PubMed Web of Science ®Google Scholar
• Cao RY, Zheng H, Redfearn D, et al. Fndc5: a Novel Player in Metabolism and Metabolic Syndrome. Biochimie. 2019;158:111–116.
   PubMed Web of Science ®Google Scholar
• Wu S, Yi J, Zhang YG, et al. Leaky Intestine and Impaired Microbiome in an Amyotrophic Lateral Sclerosis Mouse Model. Physiol Rep. 2015;3(4):pii: e12356.
   Web of Science ®Google Scholar
• Fang X, Wang X, Yang S, et al. Evaluation of the Microbial Diversity in Amyotrophic Lateral Sclerosis Using High-Throughput Sequencing. Front Microbiol. 2016;7:1479.
   PubMed Web of Science ®Google Scholar
• Rowin J, Xia Y, Jung B, et al. Gut Inflammation and Dysbiosis in Human Motor Neuron Disease. Physiol Rep. 2017;5(18):pii: e13443.
   PubMed Web of Science ®Google Scholar
• Brenner D, Hiergeist A, Adis C, et al. The Fecal Microbiome of Als Patients. Neurobiol Aging. 2018;61:132–137.
   PubMed Web of Science ®Google Scholar
• Mazzini L, Mogna L, De Marchi F, et al. Potential Role of Gut Microbiota in Als Pathogenesis and Possible Novel Therapeutic Strategies. J Clin Gastroenterol. 2018;52(suppl 1):S68–S70.
   PubMedGoogle Scholar
• Zhang YG, Wu S, Yi J, et al. Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis. Clin Ther. 2017;39(2):322–336.
   PubMed Web of Science ®Google Scholar
• Ngo SR R, McRae AF, van Eijk RPA, et al. Progression and Survival of Patients with Motor Neuron Disease Relative to Their Faecal Microbiota. Amyotrophic Lateral Scler Fronttemporal Degener. 2020. doi:110.1080/21678421.2020.177285
   Web of Science ®Google Scholar
• Lee J-M, Wheeler V, Chao M, Consortium GmoHsD. Identification of Genetic Factors That Modify Clinical Onset of Huntington’s Disease. Cell. 2015;162(3):516–526.
   PubMed Web of Science ®Google Scholar
• Kuchenbaecker KB, McGuffog L, Barrowdale D, et al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in Brca1 and Brca2 Mutation Carriers. JNCI: Journal of the National Cancer Institute. 2017;109(7). DOI:10.1093/jnci/djw302.
   PubMedGoogle Scholar
• Visscher PM, Wray NR, Zhang Q, et al. 10 Years of GWAS Discovery: biology, Function, and Translation. Am J Hum Genet. 2017;101(1):5–22.
   PubMed Web of Science ®Google Scholar
• Lecarpentier J, Silvestri V, Kuchenbaecker KB, et al. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017;35(20):2240–2250.
   PubMed Web of Science ®Google Scholar
• Fahed AC, Wang M, Homburger JR, et al. Polygenic Background Modifies Penetrance of Monogenic Variants Conferring Risk for Coronary Artery Disease, Breast Cancer, or Colorectal Cancer. medRxiv. 2019.
   Google Scholar
• Han X, Qassim a, An J, et al. Genome-Wide Association Analysis of 95 549 Individuals Identifies Novel Loci and Genes Influencing Optic Disc Morphology. Hum Mol Genet. 2019;28(21):3680–3690.
   PubMed Web of Science ®Google Scholar
• Chen K, Bennett SA, Rana N, et al. Neurodegenerative Disease Proteinopathies Are Connected to Distinct Histone Post-Translational Modification Landscapes. ACS Chem Neurosci. 2018;9(4):838–848.
   PubMed Web of Science ®Google Scholar
• Nabais MF, Lin T, Benyamin B, et al. Significant out-of-Sample Classification from Methylation Profile Scoring for Amyotrophic Lateral Sclerosis. NPJ Genom Med. 2020;5(1):10.
   PubMed Web of Science ®Google Scholar
• Consortium G, Deluca DS, Segre AV. Human Genomics. The Genotype-Tissue Expression (Gtex) Pilot Analysis: multitissue Gene Regulation in Humans. Science. 2015;348(6235):648–660.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zhang F, Hu H, et al. Integration of Summary Data from GWAS  and eQTL Studies Predicts Complex Trait Gene Targets. Nat Genet. 2016;48(5):481–487.
   PubMed Web of Science ®Google Scholar
• Neumeyer S, Hemani G, Zeggini E. Strengthening Causal Inference for Complex Disease Using Molecular Quantitative Trait Loci. Trends Mol Med. 2020;26(2):232–241.
   PubMed Web of Science ®Google Scholar